Testing higher doses of two TB drugs in a shorter treatment course
Tests higher doses of rifampicin and pyrazinamide in adults with mild-to-moderate tuberculosis.
Key facts
- Who runs it
- Region Oestergoetland
- Where
- Linkoping and Norrkoping, SwedenSee the 2 sites
- Registry title
- A randomised, prospective phase II study of pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in a shortened treatment of mild-to-moderate tuberculosis compared with standard of care
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 18 Oct 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 18 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active tuberculosis of the lungs that responds to the usual TB drugs. They have not yet started treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Active tuberculosis of the lungs, confirmed by a positive culture or a positive PCR test for M. tuberculosis-complex. The record also describes the trial as for mild-to-moderate TB.
- Earlier treatment
- Must be assigned to first-line TB drugs but not yet started them. Cannot have had treatment for active TB in the past 12 months.
- Biomarker or test result
- Positive culture or positive PCR test for M. tuberculosis-complex. No resistance to RIF, INH, PZA or EMB.
Main reasons for not taking part
- Treatment for active TB in the past 12 months
- Resistance to any of the standard TB drugs (RIF, INH, PZA, EMB)
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Confirmed active pulmonary tuberculosis, through positive culture or positive PCR test for M.tuberculosis-complex
- Has provided written consent
- Assigned for TB-treatment (first-line drugs) but not yet started treatment
Who cannot take part
- Has received treatment for active TB in the past 12 months leading up to inclusion in the study
- Resistance to any of the drugs (RIF, INH, PZA, EMB) included in the standard TB treatment according to molecular biological or phenotypic drug susceptibility testing
Where in Sweden
- Region OestergoetlandLinkoping, SwedenTaking people
- Vrinnevisjukhuset I Norrkoeping Region OestergoetlandNorrkoping, SwedenTaking people
About the trial
What the trial wants to find out
The main aim of the study is to investigate strategies for reducing the length of TB treatment through detailed study of a shorter TB treatment based on higher doses of RIF and PZA, for a selected group of patients with drug-sensitive pulmonary TB.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A randomised, prospective phase II study of pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in a shortened treatment of mild-to-moderate tuberculosis compared with standard of care
- Plain-language title
- Testing higher doses of two TB drugs in a shorter treatment courseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 October 2024